MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-13-2025
DURECT Corporation Cost of Revenue 2011-2026 | DRRX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue DURECT Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.72 M | 1.59 M | 1.96 M | 1.41 M | 1.26 M | 1.64 M | 6.63 M | 5.29 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.63 M | 1.26 M | 2.69 M |
Quarterly Cost of Revenue DURECT Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 K | - | 513 K | 27 K | 289 K | 312 K | 359 K | 388 K | - | 345 K | 393 K | 335 K | - | 364 K | 359 K | 352 K | - | 339 K | 253 K | 396 K | - | 731 K | 879 K | 1.14 M | - | 912 K | 1.08 M | 1.17 M | - | 3.1 M | 924 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.1 M | 7 K | 624 K |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.17 | -1.3 % | $ 126 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
6.21 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
705 M | $ 12.87 | 3.04 % | $ 659 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | $ 21.5 | -0.12 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
84 M | $ 6.16 | -8.33 % | $ 382 M | USA |
 |
Harrow Health
HROW
|
39.6 M | $ 52.73 | 5.65 % | $ 1.72 B | USA |
 |
Jupiter Wellness
JUPW
|
3.15 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
6.51 M | $ 1.22 | 0.83 % | $ 21.3 M |  China |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.7 | -2.02 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 4.02 | 1.01 % | $ 56.5 M | USA |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 4.34 | -6.36 % | $ 571 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.71 | -2.01 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 3.83 | 5.27 % | $ 4.75 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 25.49 | 4.19 % | $ 1.18 B | USA |
 |
Rockwell Medical
RMTI
|
74.9 M | $ 0.97 | 12.89 % | $ 22.6 M | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
2.83 B | $ 14.41 | 3.74 % | $ 1.98 B | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
11 M | $ 2.29 | 0.66 % | $ 309 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 1.01 | -12.93 % | $ 4.36 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 4.09 | -6.52 % | $ 123 M | USA |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
27 M | $ 9.32 | 1.97 % | $ 662 M | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.64 | -0.45 % | $ 30.6 M | USA |
 |
Tilray
TLRY
|
480 M | $ 9.4 | -3.34 % | $ 5.81 B | Canada |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 1.79 | 8.18 % | $ 18.7 M | USA |
 |
Zomedica Corp.
ZOM
|
7.87 M | - | -0.21 % | $ 98 M | USA |